



The Illinois Medical Bulletin



The Role of C-Reactive Protein in Predicting Atherosclerotic Cardiovascular Disease Risk: A Review of the Evidence from 2000-2010

¹A.Bent, ²A. Benton

^{1,2} University of Illinois College of Medicine

Corresponding Email : bentmd284847@gmail.com

Article History :

Received date : 2011/10/12
Revised date : 2011/11/28
Accepted date : 2011/12/09
Published date : 2012/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: The first decade of the 21st century heralded a paradigm shift in cardiology, moving from a purely lipid-centric model of atherosclerosis to one that embraced the disease as a chronic inflammatory process. Within this new framework, high-sensitivity C-reactive protein (hs-CRP), a downstream marker of systemic inflammation, emerged as a leading biomarker. This review synthesises the pivotal literature published between 2000 and 2010 that established the relationship between elevated hs-CRP and the risk of atherosclerotic cardiovascular disease.

Literature Review: A substantial body of evidence from large-scale prospective studies and meta-analyses during this period consistently demonstrated that hs-CRP was a powerful and independent predictor of future cardiovascular events, including myocardial infarction and stroke. Its predictive value was shown to be additive to that of traditional risk factors, including lipid levels. The pathophysiological basis was clarified, with research confirming that

inflammation mediates every stage of atherogenesis, from lesion initiation to plaque rupture. Consequently, clinical practice guidelines were issued recommending the use of hs-CRP for enhanced risk stratification in select patient groups. This "inflammation hypothesis" was ultimately validated in a landmark clinical trial, JUPITER, which showed that targeting individuals with elevated hs-CRP with statin therapy significantly reduced major cardiovascular events, even in those with normal cholesterol levels.

Conclusion: The evidence from 2000-2010 conclusively established hs-CRP as a valuable biomarker for cardiovascular risk assessment and solidified inflammation as a central, modifiable component in the pathogenesis of atherosclerosis.

Keywords: C-Reactive Protein (CRP), Atherosclerosis, Inflammation, Cardiovascular Disease, Risk Prediction.

INTRODUCTION

For decades, the understanding of atherosclerotic cardiovascular disease was dominated by the lipid hypothesis, focusing on the deposition of cholesterol within the arterial wall as the primary pathogenic event. However, the period between 2000 and 2010 witnessed a fundamental evolution in this understanding. A wealth of research recast atherosclerosis as a dynamic, chronic inflammatory disease, a paradigm shift that opened new avenues for risk prediction and treatment (Libby, 2002). This new "inflammation hypothesis" proposed that an inflammatory response within the vessel wall was critical to the initiation, progression, and ultimate thrombotic complications of atherosclerosis.

In the search for reliable biomarkers of this underlying vascular inflammation, high-sensitivity C-reactive protein (hs-CRP) emerged as the most extensively studied and clinically validated candidate. Hs-CRP is an acute-phase reactant protein synthesised by the liver, primarily in response to the cytokine interleukin-6. Its stable, low-level elevations were found to reflect chronic, low-grade inflammation. This literature review aims to synthesise the pivotal research published between 2000 and 2010 that defined the role of hs-CRP as a key predictor of cardiovascular risk and cemented inflammation as a core component of atherosclerotic disease.

LITERATURE REVIEW

The argument for hs-CRP as a cardiovascular risk marker was built upon three pillars of research prominent in the 2000-2010 decade: large-scale epidemiological evidence, clarification of its clinical utility, and validation through a landmark intervention trial.

First, numerous prospective cohort studies established hs-CRP as a strong and independent predictor of future cardiovascular events. A seminal study by Ridker et al. (2002) directly compared hs-CRP with LDL cholesterol for predicting first cardiovascular events among healthy women and found that hs-CRP was a stronger predictor. This finding was replicated across diverse populations and was consolidated in a major meta-analysis by Danesh et al. (2004), which pooled data from 22 studies. The analysis confirmed a continuous, graded relationship between hs-CRP levels and the risk of coronary heart disease, independent of traditional risk factors. These powerful epidemiological data made a compelling case that measuring inflammation provided prognostic information beyond that offered by lipid screening alone.

Second, based on this mounting evidence, the clinical utility of hs-CRP was formally addressed. In 2003, the Centers for Disease Control and Prevention (CDC) and the American Heart Association (AHA) co-published a scientific statement outlining the appropriate use of hs-CRP in clinical practice (Pearson et al., 2003). They concluded that hs-CRP was an optional but valuable tool for refining global risk assessment, particularly for patients deemed to be at intermediate risk (e.g., 10-20% 10-year risk) by standard models like the Framingham Risk Score. For these individuals, an elevated hs-CRP level could justify more aggressive risk factor modification, while a low level might provide some reassurance. This publication codified the role of hs-CRP, moving it from a research tool to a component of clinical decision-making.

The third and most definitive pillar of evidence came from interventional research. The "inflammation hypothesis" held that if inflammation was causal, then targeting it should reduce risk. This was tested directly in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial. This landmark study enrolled healthy individuals with low-to-normal LDL cholesterol (<130 mg/dL) but elevated hs-CRP (≥ 2.0 mg/L). The trial, published by Ridker et al. (2008), was stopped early because of the profound benefit observed in the treatment group. Rosuvastatin therapy resulted in a 44% reduction in the primary endpoint, a composite of major cardiovascular events. JUPITER provided the first large-scale trial evidence that treating patients selected on the basis of an inflammatory

biomarker, independent of high cholesterol, resulted in a significant clinical benefit, thereby validating the role of inflammation in atherothrombosis.

CONCLUSION

The decade of 2000 to 2010 was a period of profound transformation in the understanding and management of atherosclerotic cardiovascular disease. The literature from this era conclusively demonstrated that inflammation is not an innocent bystander but a critical participant in the disease process. High-sensitivity C-reactive protein was firmly established as a robust, accessible, and independent biomarker of underlying cardiovascular risk.

Through a progression of large-scale observational studies, formal clinical practice guidelines, and a definitive randomised controlled trial, the role of hs-CRP was clarified. It was validated as a tool to enhance risk prediction and, more importantly, to identify a population of patients who would benefit from targeted therapy. The successful outcome of the JUPITER trial provided the ultimate proof-of-concept for the inflammation hypothesis of atherosclerosis, cementing a new standard of care and shaping cardiovascular medicine for years to come.

REFERENCES

- Danesh, J., Wheeler, J.G., Hirschfield, G.M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G.D., Pepys, M.B. and Gudnason, V. (2004) 'C-Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease', *New England Journal of Medicine*, 350(14), pp. 1387-1397.
- Libby, P. (2002) 'Inflammation in atherosclerosis', *Nature*, 420(6917), pp. 868-874.
- Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Cannon, R.O., 3rd, Criqui, M., Fadl, Y.Y., Fortmann, S.P., Hong, Y., Myers, G.L., Rifai, N., Smith, S.C., Jr., Taubert, K., Tracy, R.P. and Vinicor, F. (2003) 'Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association', *Circulation*, 107(3), pp. 499-511.
- Ridker, P.M., Rifai, N., Rose, L., Buring, J.E. and Cook, N.R. (2002) 'Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events', *New England Journal of Medicine*, 347(20), pp. 1557-1565.

Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M., Jr., Kastelein, J.J., Koenig, W., Libby, P., Lorenzatti, A.J., MacFadyen, J.G., Nordestgaard, B.G., Shepherd, J., Willerson, J.T. and Glynn, R.J. (2008) 'Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein', *New England Journal of Medicine*, 359(21), pp. 2195-2207.